← Back to Screener
Alnylam Pharmaceuticals, Inc. (ALNY)
Price$295.63
Value ScoreD
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-48.19%
Price vs S&P 500 (4W)-2.99%
VGM Score49.07
Market Capitalization$40.43B
P/E Ratio (Annual)128.85x
All Metrics
P/CF (Annual)77.14x
Book Value / Share (Quarterly)$8.06
P/TBV (Annual)2.64x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)52.98%
Cash Flow / Share (Quarterly)$4.81
Price vs S&P 500 (YTD)-34.99%
Gross Margin (TTM)80.83%
Net Profit Margin (TTM)13.46%
EPS (TTM)$4.18
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$4.18
Revenue Growth (5Y)49.77%
EPS (Annual)$2.33
ROI (Annual)9.00%
Gross Margin (Annual)81.64%
Net Profit Margin (5Y Avg)-47.61%
Cash / Share (Quarterly)$22.55
P/E Basic Excl Extra (TTM)70.04x
Revenue Growth QoQ (YoY)96.43%
P/E Normalized (Annual)128.85x
ROA (Last FY)6.32%
Revenue Growth TTM (YoY)82.57%
EBITD / Share (TTM)$5.64
ROE (5Y Avg)-133.18%
Operating Margin (TTM)16.55%
Cash Flow / Share (Annual)$3.52
P/B Ratio37.59x
P/B Ratio (Quarterly)41.05x
Net Income / Employee (Annual)$125,500
EV / Revenue (TTM)9.66x
Net Interest Coverage (TTM)3.25x
ROA (TTM)11.83%
EV / EBITDA (TTM)54.19x
EPS Incl Extra (Annual)$2.33
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)2.88x
3-Month Avg Trading Volume1.22M
52-Week Price Return3.10%
EV / Free Cash Flow (Annual)89.01x
P/E Incl Extra (TTM)70.04x
Revenue / Employee (TTM)$1,714,800
Tangible BV / Share (Quarterly)$3.38
P/S Ratio (Annual)10.89x
Asset Turnover (Annual)0.75x
52-Week High$495.55
Operating Margin (5Y Avg)-35.59%
EPS Excl Extra (Annual)$2.33
CapEx CAGR (5Y)-3.57%
Tangible BV CAGR (5Y)21.68%
26-Week Price Return-32.26%
Quick Ratio (Annual)2.51x
13-Week Price Return-8.83%
Total Debt / Equity (Annual)3.42x
Current Ratio (Quarterly)3.13x
Enterprise Value$41.42B
Revenue / Share Growth (5Y)45.11%
Asset Turnover (TTM)0.88x
Book Value / Share Growth (5Y)-14.26%
Revenue / Employee (Annual)$1,485,600
Inventory Turnover (Annual)8.46x
Pretax Margin (Annual)8.70%
Cash / Share (Annual)$21.97
3-Month Return Std Dev34.21%
Gross Margin (5Y Avg)83.48%
Net Income / Employee (TTM)$230,900
ROE (Last FY)39.76%
Net Interest Coverage (Annual)3.79x
EPS Basic Excl Extra (Annual)$2.33
P/FCF (TTM)63.04x
Receivables Turnover (TTM)7.71x
EV / Free Cash Flow (TTM)64.59x
Total Debt / Equity (Quarterly)2.52x
EPS Incl Extra (TTM)$4.18
Receivables Turnover (Annual)7.20x
ROI (TTM)18.14%
P/S Ratio (TTM)9.43x
Pretax Margin (5Y Avg)-48.27%
Revenue / Share (Annual)$27.58
Tangible BV / Share (Annual)$3.73
Forward P/E34.43x
Price vs S&P 500 (52W)-25.11%
P/E Ratio (TTM)70.04x
Year-to-Date Return-24.06%
5-Day Price Return1.52%
EPS Normalized (Annual)$2.33
ROA (5Y Avg)-13.41%
Net Profit Margin (Annual)8.45%
Month-to-Date Return-2.43%
Cash Flow / Share (TTM)$-3.62
EBITD / Share (Annual)$3.82
Operating Margin (Annual)12.36%
LT Debt / Equity (Annual)3.14x
P/CF (TTM)56.71x
ROI (5Y Avg)-40.42%
P/E Excl Extra (TTM)70.04x
LT Debt / Equity (Quarterly)2.31x
EPS Basic Excl Extra (TTM)$4.18
P/TBV (Quarterly)5.56x
P/B Ratio (Annual)66.57x
Inventory Turnover (TTM)10.99x
Pretax Margin (TTM)13.68%
Book Value / Share (Annual)$5.96
Price vs S&P 500 (13W)-18.58%
Beta0.25x
P/FCF (Annual)86.87x
Revenue / Share (TTM)$31.01
ROE (TTM)98.29%
52-Week Low$284.28
vGradeD
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 261.51est. 0.96
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.97
4.00
3.94
3.94
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | D | A | C | $295.63 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics with five FDA-approved drugs generating revenue across rare genetic diseases and cardio-metabolic indications. The company has an expanding pipeline in genetic medicines, hepatic infectious diseases, and CNS/ocular diseases, with multiple programs in clinical development. Partnership upfront fees and upcoming milestone and royalty payments from collaborations provide additional cash generation and revenue diversification beyond its commercial portfolio.